---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292803852.md"
description: "Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164."
datetime: "2026-07-15T17:49:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292803852.md)
  - [en](https://longbridge.com/en/news/292803852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292803852.md)
generator: "portal-rs"
---

# 

Veradermics shares are trading higher after the company released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. Also, Needham maintained its Buy rating on the stock and raised its price target from $136 to $164.

### Related Stocks

- [MANE.US](https://longbridge.com/en/quote/MANE.US.md)

## Related News & Research

- [Montanova Capital reports disposal of 750,000 Veradermics common shares worth $80.44 million](https://longbridge.com/en/news/296656843.md)
- [Veradermics to discuss Phase 2 results for oral minoxidil hair-loss drug VDPHL01 on July 15 webcast](https://longbridge.com/en/news/292682761.md)
- [Teladoc’s Completed BetterHelp Trial Signals a New Phase for Digital Mental Health Investing](https://longbridge.com/en/news/297070880.md)
- [Sagimet advances AURORA Phase 3 acne trial of denifanstat, targets Q4 2026 enrollment](https://longbridge.com/en/news/296901945.md)
- [Veradermics to present age-subgroup data from VDPHL01 male hair loss trial at AAD Innovation Academy](https://longbridge.com/en/news/293029911.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**